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Abstract 
Four tricyclic lactams that structurally resemble alkaloids with the pancratistatin 
skeleton were synthetized from bromobenzene by a chemoenzymatic strategy.  
The sequence involved enzymatic dihydroxylation, efficient stereodirected 
oxidation of double bonds, inter- or intramolecular Hüisgen cycloaddition and a 
solvent free cyclization. The complex structures were obtained in high chemical 
and optical purity and can be good candidates for biological testing.      
 
Introduction 
Alkaloids isolated from plants of the Amaryllidaceae family exhibit a wide 
structural diversity.1 Structures are complex involving polycyclic systems, 
aromatic and aliphatic rings and often several contiguous chiral centers. 
Traditional medicine alludes to Amaryllidaceae plant extracts to treat several 
diseases. Notably, extracts of daffodil, Narcissus poeticus L. were described by 
Hippocrates for the treatment of uterine tumors.2 Pure alkaloids isolated from 
the family are known anti-infective agents (antibacterial, antiparasitic and 
antiviral) and exhibit other biological properties.3  
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Pancratistatin selectively induces apoptosis in cancer cells, but, the low 
availability of the natural alkaloid has obstructed its clinical studies and 
delayed progress. Recently, a recent report has summarized the advances in 
pancratistatin and pancratistatin unnatural analogues and concomitantly shed 
light on the mechanism of action of these molecules.4 This relevant report 
stated that pancratistatin acts on mitochondria to promote apoptosis and 
therefore disclosed the possibility of a new chemotherapy approach. 
Comparable results were also disclosed by Griffin et al. showing that natural 
pancratistatin induced apoptosis in cultivated colon cancer cells and reduced 
colon cancer in vivo.  Some of the results suggested that the target of 
pancratistatin was mitochondria in cancer cells without affecting non-tumoral 
cell lines.5  
Among the group, isocarbostyril alkaloids (Figure 1) are characterized for their 
isoquinolinone parent structure and the presence of an amidic nitrogen as part 
of a lactam ring. In a notable series of papers the Hudlicky group has developed 
not only efficient synthesis for several alkaloids of the pancratistatin family, but 
also discovered unnatural analogues of unsurpassed potency and 
bioavailability.4, 6 
 
Figure 1. The four alkaloids of the pancratistatin group 
In recent years, the demand for methodologies and reactions that rapidly build 
structural complexity has grown exponentially, meeting three main 
requirements: efficiency, versatility and selectivity. Reactions with these main 
characteristics fall within the modern concept of "Click Chemistry" defined by 
Sharpless in 2001.7 This group of reactions, or synthetic methodologies, allow 
the medicinal chemists to quickly generate compound libraries to test and keep 
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up with the vast amount of information provided by modern biological screening 
techniques, thus accelerating the process of drug discovery.  
Hüisgen cycloaddition reemerged in its Cu(I) catalyzed version as the 
archetypic Click Chemistry reaction.8 However, for this project we found that 
Cu(I) catalysis was not required since high reactivity was achieved by using a 
doubly activated symmetric alkyne and an entropically favored intramolecular 
[2+3] reaction.  
In this sense, we prepared two pancratistatin analogues utilizing uncatalyzed 
versions of the Hüisgen reaction. The molecules resemble the natural alkaloid, 
as they mimic the cyclitol residue, yet the phenyl ring is substituted by a 
heteroaromatic triazole.  
 
Results and discussion 
Cyclitol ring C has been previously prepared by Hudlicky et al. in a remarkable 
sequence of research papers involving enzymatic dihydroxylation of aromatic 
compounds for the initial introduction of asymmetry.6a, 6h, 9 We have previously 
used this same strategy in the synthesis of several cyclitols10 and in our own 
first approach to pancratistatin analogs.10d Initially, the starting material was 
prepared by oxidation of bromobenzene with a mutant strain of P. putida 
discovered by Gibson et al. in the late 60s.11 Later, the development of 
recombinant strains that overexpress toluene dioxygenase (TDO) allowed the 
involved chemists to have available a supply of multigram quantities of the 
homochiral cyclohexadiene diol 2 to be used in a wide variety of synthetic 
ventures.10j, 12  Currently, the highest reported yield of 2 is around 40 G per liter 
of culture medium.13 This result, obtained in our Department, can provide 
enough mass of optically pure precursor to support the work of several synthetic 
groups including ours. This diol 2 was protected as the corresponding acetonide 
and the later was transformed with excellent regio- and stereoselectivity using 
N-iodosuccinimide (NIS) into iodohydrin 4 as the major stereoisomer.12e 
Compound 4 was subjected to basic treatment to obtain an epoxide which was 
dehalogenated under classic radical conditions utilizing HBu3Sn as hydrogen 
donor and azobisisobutyronitrile (AIBN) as initiator14 in order to access epoxide 
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6 (Scheme 1). Under these experimental conditions two new byproducts (6a 
and 6b) were observed, therefore decreasing the reaction yield. These 
byproducts, inseparable alongside compound 6, were identified by NMR and 
MS. Fortunately; this problem was successfully solved recycling 6b into starting 
material and 6a into the desired product (Scheme 2). Epoxide 6 was 
transformed into aziridine 9 as reported by Yadav et al.15 by nucloephilic ring 
opening with sodium azide, mesylation of the free alcohol and exposing this 
compound to Staudinguer reduction conditions.16 Finally, aziridine 9 was 
opened with sodium azide to provide key compound 10 in 15% overall yield 
from diol 2. 
 
Scheme 1. Strategy towards the key 1,2-aminoazidocyclitol intermediate 10. a) 
toluene dioxigenase in E. coli JM109 (pDTG601), 40 g/L; b) DMP, acetone, p-
TsOH, r.t., 30 min, 90%; c) NIS, DME:H2O (3:1), 0 °C, 17 h, 75%; d) NaOH, 
DME:H2O (3:1), 0 °C, 40 min., 95%; e) HBu 3Sn, AIBN, THF, reflux, 4 h, 61%; f) 
NaN3, NH4Cl, THF:EtOH:H2O (3:3:1) reflux, 40 min, 77%; g) MsCl, Et3N, 
CH2Cl2, r.t., 1 h, 95%; h) TPP, DIPEA, THF:H2O (4:1), reflux, 4h, 60%; i) NaN3, 
NH4Cl, THF:EtOH:H2O (3:3:1), reflux, 40 min., 85%. 
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Scheme 2. Recycling cycle of the byproducts detected in the dehalogenation 
process. a) HBu3Sn, AIBN, THF, reflux, 4 h, 61%; b) DBU, CH2Cl2, R.T., 
quantitative. 
 
With compound 10 in hand we studied several amidation conditions and 
conclude that classical coupling conditions with DCC/DMAP in dry CH2Cl2 as 
solvent were the best providing 11 in 50% yield. Amide 11 underwent 
intramolecular Hüisgen cycloaddition when heated in toluene, to render 
compound 14a (Route 1, Scheme 3). Another route (Route 2) was explored 
starting from 10 in which the amine group was also protected, in this case with a 
labile di-tert-butyl dicarbonate group, to allow an easier removal later in the 
synthesis. Protection yielded compound 12 that reacted with a symmetric 
alkyne to give the intermolecular Hüisgen cycloaddition product, triazole 13 in 
high yield (Route 2, Scheme 3). Interestingly, the catalyzed version of the 
Hüisgen reaction was also used on chiral derivatives of cyclohexadiene diols by 
Lewis et al.17 to render a chiral triazole carboxylic acid methyl ester from the 
corresponding alkyne. 
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Scheme 3. Complementary approaches to tricyclic lactams.  a) Propiolic 
acid, DCC, DMAP, CH2Cl2, 0 ºC, 50 min, 50%; b) toluene, reflux, 30 min, 
60%; c) Boc2O, NaOH, H2O/t-BuOH, (2/1), 0°C, 24 h, 89%; d) 
Diethylacetylendicarboxylate (DADC), toluene, reflux, 2 h, 90%; e) SiO2, 
110°C, 6 h, 71%. 
 
Following a procedure reported by Hudlicky et al.18 for the synthesis of other 
pancratistatin analogues we adsorbed triazole 13 in silica gel and heated the 
solid mixture to 110 °C.  Compound 13 cyclized to provide lactam 14b in more 
than 70% yield. In this reaction, we detected, as a minor byproduct, the 
interesting derivative 15, which was identified by NMR as an isomer of 
compound 14b (Scheme 4). This compound probably resulted from the 
thermodynamically favored migration of the olefin to a conjugated position. 
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Scheme 4. Byproduct observed during cyclization of diester 13. 
 
The next goal was to functionalize cyclitol ring C. For this purpose, we 
dihydroxylated the olefin present in compounds 14a and 14b. Our previous 
experience in the dihydroxylation of similar systems10i, 19 including lactone 
analogous of pancratistatin indicated that classical osmium tetroxide oxidation 
will not react with our substrates. Therefore, we tried the stronger and greener 
oxidation system RuCl3/NaIO4. We used a precisely defined mixture of solvents, 
CH3CN/AcOEt/H2O (3/3/1), in order to avoid oxidative cleavage of the double 
bond.19a Both precursors delivered a mixture of diastereomers with the anti 
product as the major isomer (Scheme 5). This result was expected due to the 
blocking effect of the β-face of the isopropylidene group which directed the 
reaction. 
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Scheme 5. Dihydroxylation and preparation of the alkaloid analogues. a) RuCl3, 
NaIO4, CH3CN/AcOEt/H2O (3/3/1), 0ºC, 10 min; b) Ac2O, Et3N, DMAP, CH2Cl2, 
0 ºC, 30 min, 67%; c) DOWEX acidic resin, H2O, T=90 °C, 1 h; d) Ac 2O, Et3N, 
DMAP, CH2Cl2, 0 ºC, 30 min, 70%. 
 
Structure-activity studies performed on the natural product showed that in order 
to maintain biological activity, the hydroxyl group in C2 position must be anti to 
the diol function in C3-C4.6g, 20 For this reason we focused our interest in the 
obtained anti products, 16 and 20 which were completely characterized as the 
corresponding diacetates 17 and 21. Stereochemical assignment of 16 was 
confirmed by X-ray diffraction analysis (Figure 2). 
 
Figure 2. X-ray diffraction analysis of compound 16. 
 
The endgame towards our final products 19 and 23, involved protecting the 
alcohols at positions C1 and C2 first, and exchanging the isopropylidene group 
at positions C3 and C4 for acetate protecting groups. In order to synthesize 
compounds with a higher degree of similarity to the natural product we 
synthesize tetraols 24 and 25 starting from compounds 16 and 20, deprotecting 
alcohols at positions C3 and C4 with acidic DOWEX resin using deuterated 
water as solvent to monitor consumption of the starting material analyzing 
directly from the reaction mixture by NMR (Scheme 6). In the case of compound 
20 we had an ester group prone to undergo hydrolysis in these conditions. This 
required larger amounts of resin and longer reaction times. 
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Summarizing, we managed to synthesize two analogues of these alkaloids, 
compound 24, analogue to 7-deoxypancratistatin, and compound 25 analogue 
to pancratistatin, due to the carboxylic acid triazole substituent. These 
compounds were synthesized from a common precursor, the aminoazide 10, 
with a global yield of 14% for compound 24 in four steps and 27% for compound 
25 in five steps. Stereochemical assignment of 24 was confirmed by X-ray 
diffraction analysis (Figure 3). 
  
Scheme 6. Synthesis of tetraols 24 and 25 alkaloid analogues of 7-
deoxypancratistatin and pancratistatin respectively. 
 
 
Figure 3. X-ray diffraction analysis of compound 24. 
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